Investigation of the combined efficacy of two Haemonchus contortus vaccines in weaner Merino sheep.

This study was conducted to investigate whether co-administration of Barbervax® (Bvax) with Haemonchus contortus surface larval antigen (HcsL3) would increase the protective efficacy and duration of protection against H. contortus infection in weaner Merino sheep. A total of 132 10-month-old weaned Merino ewe lambs were randomly allocated into six treatment groups (n = 22).

Protective efficacy of Barbervax® in Merino weaner sheep trickle infected with five doses of Haemonchus contortus infective larvae.

Barbervax® protects sheep against H. contortus infection; however, the level of protection afforded by the vaccine at different levels of larval challenge under field conditions has not been reported. Therefore, this study was designed to investigate the protective efficacy of Barbervax® at increasing doses of trickle infection with H.

Evaluation of Barbervax® vaccination for lambing Merino ewes.

The Barbervax® vaccine, directed against Haemonchus contortus, has been commercially available in Australia since 2014. However, to date the optimal timing for booster vaccination of lambing ewes has not been identified. Therefore the aim of this experiment was to compare the efficacy of Barbervax® when administered to ewes one week prior to the commencement of lambing versus at lamb marking 7 weeks later.

First report on seroepidemiology of Toxoplasma gondii infection in pigs in Central Ethiopia.

Background: Toxoplasma gondii is one of the most widely prevalent cyst forming Apicomplexan parasites with significant impact on animal production particularly in sheep, goats and pigs. The objectives of this cross-sectional study were to estimate the seroprevalence and to assess risk factors of Toxoplasma gondii infection in pigs. A systematic random sampling technique was used to collect 402 blood samples from pigs in Central Ethiopia.